Kangstem Biotech Balance Sheet Health
Financial Health criteria checks 6/6
Kangstem Biotech has a total shareholder equity of ₩50.1B and total debt of ₩11.5B, which brings its debt-to-equity ratio to 23%. Its total assets and total liabilities are ₩81.3B and ₩31.1B respectively.
Key information
23.0%
Debt to equity ratio
₩11.53b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩37.36b |
| Equity | ₩50.12b |
| Total liabilities | ₩31.13b |
| Total assets | ₩81.25b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A217730's short term assets (₩47.4B) exceed its short term liabilities (₩18.6B).
Long Term Liabilities: A217730's short term assets (₩47.4B) exceed its long term liabilities (₩12.5B).
Debt to Equity History and Analysis
Debt Level: A217730 has more cash than its total debt.
Reducing Debt: A217730's debt to equity ratio has reduced from 36.6% to 23% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A217730 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A217730 has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 0.4% each year.